PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer - Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study

被引：0
|
作者：
Loibl, S.
Budczies, J.
Weichert, W.
Furlanetto, J.
Stenzinger, A.
Pfarr, N.
von Minckwitz, G.
Jackisch, C.
Schneeweiss, A.
Fasching, P.
Schmatloch, S.
Aktas, B.
Nekljudova, V.
Weber, K.
Untch, M.
Denkert, C.
机构：
[1] German Breast Grp, Neu Isenburg, Germany
[2] Charite, Berlin, Germany
[3] Univ Hosp Heidleberg, Heidelberg, Germany
[4] Sana Klinikum Offenbach, Offenbach, Germany
[5] Univ Hosp Erlangen, Erlangen, Germany
[6] Elisabeth Krankenhaus Kassel, Kassel, Germany
[7] Univ Hosp Sen, Essen, Germany
[8] Helios Kliniken Berlin Buch, Berlin, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P3-07-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-03
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
    Jensen, J. D.
    Knoop, A.
    Laenkholm, A. V.
    Grauslund, M.
    Jensen, M. B.
    Santoni-Rugiu, E.
    Andersson, M.
    Ewertz, M.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2034 - 2042
  • [32] PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
    Jensen, J. D.
    Knoop, A.
    Laenkholm, A-, V
    Grauslund, M.
    Jensen, M-B
    Santoni-Rugiu, E.
    Andersson, M.
    Ewertz, M.
    APMIS, 2012, 120 : 16 - 16
  • [33] In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
    Janiszewska, Michalina
    Liu, Lin
    Almendro, Vanessa
    Kuang, Yanan
    Paweletz, Cloud
    Sakr, Rita A.
    Weigelt, Britta
    Hanker, Ariella B.
    Chandarlapaty, Sarat
    King, Tari A.
    Reis-Filho, Jorge S.
    Arteaga, Carlos L.
    Park, So Yeon
    Michor, Franziska
    Polyak, Kornelia
    NATURE GENETICS, 2015, 47 (10) : 1212 - +
  • [34] In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
    Michalina Janiszewska
    Lin Liu
    Vanessa Almendro
    Yanan Kuang
    Cloud Paweletz
    Rita A Sakr
    Britta Weigelt
    Ariella B Hanker
    Sarat Chandarlapaty
    Tari A King
    Jorge S Reis-Filho
    Carlos L Arteaga
    So Yeon Park
    Franziska Michor
    Kornelia Polyak
    Nature Genetics, 2015, 47 : 1212 - 1219
  • [35] Neoadjuvant pyrotinib versus pertuzumab in combination with trastuzumab and nab-Paclitaxel for patients with HER2-positive early or locally advanced breast cancer (Pyramid): A randomized, multicenter, open-label, phase 2 trial
    Zhang, Jin
    Liu, Qiang
    Jiang, Hongchuan
    Zhang, Jianguo
    Ou, Jianghua
    Chen, Dedian
    Tian, Fuguo
    Li, Yongqing
    Cheng, Xiaoming
    Ouyang, Zhong
    CANCER RESEARCH, 2022, 82 (04)
  • [36] PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer - Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies
    Loibl, S.
    Denkert, C.
    Schneeweis, A.
    Paepke, S.
    Lehmann, A.
    Rezai, M.
    Zahm, D-M
    Sinn, P.
    Khandan, F.
    Eidtmann, H.
    Dohnal, K.
    Huober, J.
    Loi, S.
    Pfitzner, B.
    Fasching, P. A.
    Andre, F.
    Lindner, J.
    Sotiriou, C.
    Guo, S.
    Gade, S.
    Nekljudova, V.
    Untch, M.
    von Minckwitz, G.
    CANCER RESEARCH, 2013, 73
  • [37] Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis
    Shi, Qiyun
    Xuhong, Juncheng
    Tian, Hao
    Qu, Man
    Zhang, Yi
    Jiang, Jun
    Qi, Xiaowei
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01):
  • [38] Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
    Mothaffar F. Rimawi
    Carmine De Angelis
    Alejandro Contreras
    Fresia Pareja
    Felipe C. Geyer
    Kathleen A. Burke
    Sabrina Herrera
    Tao Wang
    Ingrid A. Mayer
    Andres Forero
    Rita Nanda
    Matthew P. Goetz
    Jenny C. Chang
    Ian E. Krop
    Antonio C. Wolff
    Anne C. Pavlick
    Suzanne A. W. Fuqua
    Carolina Gutierrez
    Susan G. Hilsenbeck
    Marilyn M. Li
    Britta Weigelt
    Jorge S. Reis-Filho
    C. Kent Osborne
    Rachel Schiff
    Breast Cancer Research and Treatment, 2018, 167 : 731 - 740
  • [39] Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
    Rimawi, Mothaffar F.
    De Angelis, Carmine
    Contreras, Alejandro
    Pareja, Fresia
    Geyer, Felipe C.
    Burke, Kathleen A.
    Herrera, Sabrina
    Wang, Tao
    Mayer, Ingrid A.
    Forero, Andres
    Nanda, Rita
    Goetz, Matthew P.
    Chang, Jenny C.
    Krop, Ian E.
    Wolff, Antonio C.
    Pavlick, Anne C.
    Fuqua, Suzanne A. W.
    Gutierrez, Carolina
    Hilsenbeck, Susan G.
    Li, Marilyn M.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Osborne, C. Kent
    Schiff, Rachel
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 731 - 740
  • [40] Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models.
    Veeraraghavan, Jamunarani
    Mistry, Ragini
    Nanda, Sarmistha
    Bose, Sreyashree
    Liu, Chia Chia
    Sethunath, Vidyalakshmi
    Shea, Martin J.
    Mitchell, Tamika
    Anurag, Meenakshi
    Mancini, Michael A.
    Diala, Irmina
    Lalani, Alshad S.
    Stossi, Fabio
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2021, 81 (13)
12345